Dianthus Therapeutics, Inc. /DE/ Total Liabilities and Equity
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Total Liabilities and Equity of $1.21 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-04
- 2026-06-30: Liabilities and Equity $1.21B.
- 2026-03-31: Liabilities and Equity $1.25B.
- 2025-12-31: Liabilities and Equity $530.92M.
- 2025-09-30: Liabilities and Equity $577.45M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $1.21B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.25B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $530.92M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $577.45M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $326.08M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $348.58M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $374.01M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $354.25M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $368.96M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $382.46M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $179.41M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $192.46M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $78.64M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $83.44M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $83.11M 10-K · filed 2024-03-21 | $146.65M 10-K · filed 2023-03-23 |
| 2022-09-30 | $164.12M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $175.12M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $194.38M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $9.45M 8-K · filed 2023-12-21 | $189.93M 10-K · filed 2022-03-08 |
| 2021-09-30 | $206.24M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $220.38M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $144.62M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $161.62M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $174.64M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $190.73M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $144.44M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $161.51M 10-K · filed 2021-03-03 | |
| 2019-09-30 | $177.23M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $195.44M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $147.69M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $157.31M 10-K · filed 2020-03-03 | |
| 2018-09-30 | $172.79M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $180.62M 10-Q · filed 2018-08-09 | |
| 2017-12-31 | $54.46M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |